Exact Sciences, Healthmine Partner to Boost Cologuard Screening Rates via Health Plan Incentives

Exact Sciences Corporation (NASDAQ:EXAS) is one of the most promising long-term stocks to buy. On September 17, Exact Sciences formed a partnership with Healthmine, which is a member engagement and rewards platform for health plans, to boost colorectal cancer/CRC screening completion rates. The collaboration focuses on integrating Exact Sciences’ Cologuard at-home testing with health plan incentives provided through Healthmine’s platform.

The initiative is designed to close critical preventive care gaps and promote the early detection of colorectal cancer, which is a key focus area for both the NCQA’s HEDIS measures and CMS’s renewed emphasis on prevention and wellness across Medicare and Medicaid.

Members of participating health plans will receive rewards for completing and returning the noninvasive Cologuard stool DNA screening test. This incentive-driven approach is supported by Healthmine’s behavioral science-driven communications and is already proven to be effective: Healthmine’s health plan partners typically see a 25% completion improvement over baseline in CRC screening measure programs, a 52% improvement in overall gap closure across all programs, and an average 93% increase in gap closure among members in rewards programs.

Exact Sciences Corporation (NASDAQ:EXAS) provides cancer screening and diagnostic test products in the US and internationally.

While we acknowledge the potential of EXAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.